ESSA Pharma Inc Total Liabilities
ESSA Pharma Inc total liabilities. Based on the latest financial reports, ESSA Pharma Inc (EPIX) has total liabilities worth $1.60 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of ESSA Pharma Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ESSA Pharma Inc (2012–2024)
Total liabilities of ESSA Pharma Inc from 2012 to 2024. This chart illustrates how ESSA Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
ESSA Pharma Inc Competitors by Total Liabilities
The table below lists competitors of ESSA Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Agrimin Ltd
AU:AMN
|
Australia | AU$11.41 Million |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
China | CN¥477.34 Million |
|
Pan Entertainment Co. Ltd
KQ:068050
|
Korea | ₩50.32 Billion |
|
RS Public Company Limited
BK:RS
|
Thailand | ฿5.24 Billion |
|
Investcorp Credit Management BDC Inc
NASDAQ:ICMB
|
USA | $111.71 Million |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
India | Rs-456.97 Million |
|
Tian An Australia Ltd
AU:TIA
|
Australia | AU$188.16 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
India | Rs-691.15 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down ESSA Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ESSA Pharma Inc total assets.
Liquidity & Leverage Metrics
ESSA Pharma Inc Total Liabilities Ratios Explained
ESSA Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 69.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ESSA Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ESSA Pharma Inc (2012–2024)
The table below shows the annual total liabilities of ESSA Pharma Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $3.51 Million | +0.32% |
| 2023-09-30 | $3.50 Million | +46.42% |
| 2022-09-30 | $2.39 Million | -42.62% |
| 2021-09-30 | $4.16 Million | +212.57% |
| 2020-09-30 | $1.33 Million | -76.20% |
| 2019-09-30 | $5.59 Million | -18.53% |
| 2018-09-30 | $6.87 Million | -30.52% |
| 2017-09-30 | $9.88 Million | -9.67% |
| 2016-09-30 | $10.94 Million | +256.80% |
| 2015-09-30 | $3.07 Million | +37.63% |
| 2014-09-30 | $2.23 Million | +1142.16% |
| 2013-09-30 | $179.34K | +134702.32% |
| 2012-09-30 | $133.04 | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.